Business Context and Reporting Period
This Form 8-K is a current report filed by 180 Life Sciences Corp. (not Forum Markets Inc.) on August 4, 2021. The registrant is a Delaware corporation with principal executive offices in Palo Alto, CA, and its common stock (ATNF) and warrants (ATNFW) trade on The NASDAQ Stock Market LLC. The report details unregistered sales of equity securities approved by the Board of Directors effective August 4, 2021.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. The only financial data point disclosed is the exercise price for newly granted options, set at $7.56 per share, which was the closing sales price of the Company's common stock on August 3, 2021.
Material Changes and Equity Issuances
The Board of Directors approved the following unregistered equity issuances under the Company's 2020 Omnibus Incentive Plan:
- Director Options (Long-serving): Grants of options to purchase 60,000 shares each to Donald A. McGovern, Jr. and Larry Gold. These options have a 10-year term, an exercise price of $7.56, and vest monthly (1/48th) starting August 31, 2021, contingent on continued service.
- Director Options (New Appointees): Grants of options to purchase 79,000 shares each to Russell T. Ray, Teresa DeLuca, Pamela Marrone, and Francis Knuettel II. Terms match the long-serving directors (10-year term, $7.56 exercise price, monthly vesting starting August 31, 2021).
- Common Stock Issuance: Issuance of 5,135 shares to Mr. McGovern and 4,629 shares to Dr. Gold in lieu of accrued cash fees for services rendered during the quarters ended March 31, 2021, and June 30, 2021.
Guidance, Risks, and Contingencies
The filing contains no forward-looking guidance, management commentary on operations, or discussion of risks and contingencies. The securities were issued pursuant to exemptions under Section 4(a)(2) and/or Rule 506 of Regulation D of the Securities Act of 1933, as they did not involve a public offering and were offered to accredited investors or those with access to similar information. No underwriters were involved, and no underwriting discounts were paid. The securities are subject to transfer restrictions and appropriate legends.
Investor Verification Checklist
- Verify the total dilution impact of the 323,000 options and 9,764 shares of common stock issued.
- Confirm the vesting schedule commencement date of August 31, 2021, for the newly granted options.
- Review the Company's 2020 Omnibus Incentive Plan to ensure these grants were within authorized limits.
- Check subsequent filings for any changes in the Board composition or compensation structure.